Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki
{"title":"贝伐单抗慢性治疗脉络膜新生血管伴老年性黄斑变性后改用阿非利塞普。","authors":"Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki","doi":"10.1177/24741264251330334","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. <b>Methods:</b> This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. <b>Results:</b> Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (<i>P</i> < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (<i>P</i> < .05), had the best initial VA (<i>P</i> < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (<i>P</i> = .01). <b>Conclusions:</b> Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264251330334"},"PeriodicalIF":0.5000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993555/pdf/","citationCount":"0","resultStr":"{\"title\":\"Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration.\",\"authors\":\"Zofia Anna Nawrocka, Karolina Dulczewska-Cichecka, Michal Zając, Thomas A Galus, Magdalena Trębinska, Jerzy Nawrocki\",\"doi\":\"10.1177/24741264251330334\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Purpose:</b> To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. <b>Methods:</b> This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. <b>Results:</b> Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (<i>P</i> < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (<i>P</i> < .05), had the best initial VA (<i>P</i> < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (<i>P</i> = .01). <b>Conclusions:</b> Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.</p>\",\"PeriodicalId\":17919,\"journal\":{\"name\":\"Journal of VitreoRetinal Diseases\",\"volume\":\" \",\"pages\":\"24741264251330334\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2025-04-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11993555/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of VitreoRetinal Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/24741264251330334\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of VitreoRetinal Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/24741264251330334","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:介绍脉络膜新生血管(CNV)和年龄相关性黄斑变性(AMD)患者的5年解剖学和功能结局,并确定迟发性强化治疗是否能改善预后。方法:这项回顾性介入研究分析了平均39个月后进行强化治疗的眼睛的光谱域光学相干断层扫描数据和视力(VA)。收集的数据包括年龄、性别、注射频率、中央视网膜厚度、CNV类型和VA。根据疾病的活动性,每4至10周对患者进行评估。结果:对50例CNV患者50只眼进行了评价。平均初始VA为0.37 Snellen (0.58 logMAR),首次注射贝伐单抗后改善至0.44 Snellen (0.47 logMAR)。贝伐单抗转为阿非利西普治疗6个月后,各组患者VA均有显著改善(P P P P = 0.01)。结论:增加治疗频率,即使在治疗数年后,也能改善CNV和AMD患者从贝伐单抗转向阿非利西普的视力结果。
Switch to Aflibercept After Chronic Treatment With Bevacizumab for Choroidal Neovascularization With Age-Related Macular Degeneration.
Purpose: To present the 5-year anatomic and functional outcomes in patients with choroidal neovascularization (CNV) and age-related macular degeneration (AMD) and determine whether late-onset intensification of treatment results in improved outcomes. Methods: This retrospective interventional study analyzed spectral-domain optical coherence tomography data and visual acuity (VA) in eyes where treatment intensification was implemented after a mean of 39 months. Data collected included age, sex, injection frequency, central retinal thickness, type of CNV, and VA. Patients were evaluated every 4 to 10 weeks, depending on the disease activity. Results: Fifty eyes of 50 patients with CNV were evaluated. The mean initial VA was 0.37 Snellen (0.58 logMAR), which improved to 0.44 Snellen (0.47 logMAR) after the first bevacizumab injection. Six months after bevacizumab was switched to aflibercept, the improvement in VA was significant in all groups (P < .05). The VA improved throughout the 6-year observation period, with the greatest improvement in VA after the switch seen in patients who received the most injections (P < .05), had the best initial VA (P < .05), and who experienced a significantly greater improvement in VA after the first bevacizumab injection (P = .01). Conclusions: Increasing the treatment frequency, even after several years of treatment, improved visual outcomes in patients with CNV and AMD who switched from bevacizumab to aflibercept.